本帖最后由 老马 于 2013-3-13 13:43 编辑 . W7 I) Z: a: O9 F/ Y
3 e& i1 s! g: e' B" k+ b/ K/ w: l) Y健择（吉西他滨）+顺铂+阿瓦斯汀
& B8 | I+ t/ l8 M6 N# E* `' B# a Gemzar +Cisplatin + Avastin
u/ u; y! I2 ~( Ehttp://annonc.oxfordjournals.org/content/21/9/1804.full$ D* H1 M9 x" [: M# r- G9 d, Q
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) ( q- P; L: M6 Q* Z
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
+ w# s% R2 ^. |Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. $ S+ B% z! J0 }3 s, j
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 637)
; n- l) L0 u0 E/ p( J" ^# m" U华为网盘附件：
; }) J. z6 q8 c0 Z& E* z9 k: F: b( P% Q; U【华为网盘】ava.JPG$ K3 _6 L' s$ M/ |( B/ w
|
显身卡
